These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38746898)

  • 1. Design, Synthesis, and Bioevaluation of Transcriptional Enhanced Assocciated Domain (TEAD) PROTAC Degraders.
    Li H; Ge Z; Lin K; He W; Chu Q; Zheng M; Zhang S; Xu T
    ACS Med Chem Lett; 2024 May; 15(5):631-639. PubMed ID: 38746898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovering inhibitors of TEAD palmitate binding pocket through virtual screening and molecular dynamics simulation.
    Li Y; Li Y; Ning C; Yue J; Zhang C; He X; Wang Y; Liu Z
    Comput Biol Chem; 2022 Jun; 98():107648. PubMed ID: 35288361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based discovery of a novel small-molecule inhibitor of TEAD palmitoylation with anticancer activity.
    Gridnev A; Maity S; Misra JR
    Front Oncol; 2022; 12():1021823. PubMed ID: 36523977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
    Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
    Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
    Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
    Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode.
    Hu L; Sun Y; Liu S; Erb H; Singh A; Mao J; Luo X; Wu X
    Elife; 2022 Nov; 11():. PubMed ID: 36398861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging roles of TEAD transcription factors and its coactivators in cancers.
    Pobbati AV; Hong W
    Cancer Biol Ther; 2013 May; 14(5):390-8. PubMed ID: 23380592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targeting of TEAD transcription factors in cancer.
    Pobbati AV; Kumar R; Rubin BP; Hong W
    Trends Biochem Sci; 2023 May; 48(5):450-462. PubMed ID: 36709077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leveraging Hot Spots of TEAD-Coregulator Interactions in the Design of Direct Small Molecule Protein-Protein Interaction Disruptors Targeting Hippo Pathway Signaling.
    Zhao B; Pobbati AV; Rubin BP; Stauffer S
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward the Design of Ligands Selective for the C-Terminal Domain of TEADs.
    Liberelle M; Toulotte F; Renault N; Gelin M; Allemand F; Melnyk P; Guichou JF; Cotelle P
    J Med Chem; 2022 Apr; 65(8):5926-5940. PubMed ID: 35389210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Celastrol as a Novel YAP-TEAD Inhibitor for Cancer Therapy by High Throughput Screening with Ultrasensitive
    Nouri K; Azad T; Ling M; Janse van Rensburg HJ; Pipchuk A; Shen H; Hao Y; Zhang J; Yang X
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31635084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 13. An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.
    Hagenbeek TJ; Zbieg JR; Hafner M; Mroue R; Lacap JA; Sodir NM; Noland CL; Afghani S; Kishore A; Bhat KP; Yao X; Schmidt S; Clausen S; Steffek M; Lee W; Beroza P; Martin S; Lin E; Fong R; Di Lello P; Kubala MH; Yang MN; Lau JT; Chan E; Arrazate A; An L; Levy E; Lorenzo MN; Lee HJ; Pham TH; Modrusan Z; Zang R; Chen YC; Kabza M; Ahmed M; Li J; Chang MT; Maddalo D; Evangelista M; Ye X; Crawford JJ; Dey A
    Nat Cancer; 2023 Jun; 4(6):812-828. PubMed ID: 37277530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present).
    Zagiel B; Melnyk P; Cotelle P
    Expert Opin Ther Pat; 2022 Aug; 32(8):899-912. PubMed ID: 35768160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allosteric Modulation of the YAP/TAZ-TEAD Interaction by Palmitoylation and Small-Molecule Inhibitors.
    Mills KR; Misra J; Torabifard H
    J Phys Chem B; 2024 Apr; 128(16):3795-3806. PubMed ID: 38606592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-Based Design of Y-Shaped Covalent TEAD Inhibitors.
    Lu W; Fan M; Ji W; Tse J; You I; Ficarro SB; Tavares I; Che J; Kim AY; Zhu X; Boghossian A; Rees MG; Ronan MM; Roth JA; Hinshaw SM; Nabet B; Corsello SM; Kwiatkowski N; Marto JA; Zhang T; Gray NS
    J Med Chem; 2023 Apr; 66(7):4617-4632. PubMed ID: 36946421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The TEAD Family and Its Oncogenic Role in Promoting Tumorigenesis.
    Zhou Y; Huang T; Cheng AS; Yu J; Kang W; To KF
    Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26805820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of TEAD Transcription Factors in Cancer Biology.
    Huh HD; Kim DH; Jeong HS; Park HW
    Cells; 2019 Jun; 8(6):. PubMed ID: 31212916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of transgenic lines to monitor and manipulate Yap/Taz-Tead activity in zebrafish reveals both evolutionarily conserved and divergent functions of the Hippo pathway.
    Miesfeld JB; Link BA
    Mech Dev; 2014 Aug; 133():177-88. PubMed ID: 24560909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma.
    Kaneda A; Seike T; Danjo T; Nakajima T; Otsubo N; Yamaguchi D; Tsuji Y; Hamaguchi K; Yasunaga M; Nishiya Y; Suzuki M; Saito JI; Yatsunami R; Nakamura S; Sekido Y; Mori K
    Am J Cancer Res; 2020; 10(12):4399-4415. PubMed ID: 33415007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.